Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies

Launched by UNIVERSITY OF PAVIA · Mar 19, 2025

Keywords

ClinConnect Summary

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system that cause relevant disability, but also personal and familial suffering. Usually, after 10-15 years from the onset, the disease acquires a progressive clinical course or alternatively the progressive onset can open the disease, in 10-15% of cases. When MS has entered the progressive course, the disorder can be clinically active with relapses or progression, or with MRI signs of activity such as the presence of Gadolinium enhancing lesions, new T2 or enlarging lesions. While in the relapsing remittin...

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • age 25-65 years;
• • right-handed
• • progressive active form of MS treated with anti B monoclonal antibodies, Ocrelizumab or Rituximab since at least 6 months.
• • EDSS 3-7.
• • absence of relevant cognitive deficiency, as evaluated with Brief International Cognitive Assessment for MS (Bicams) °absence of visual or audio deficit disorders.
• Exclusion criteria:
• • history of a cardiovascular disorder or any other disease that can hamper the active participation to the research project.
• • Contraindication to perform MRI exams